Semaglutide is a synthetic analogue of human GLP-1, sharing 94% sequence homology with the native incretin hormone. Its extended half-life (~168 hours) is achieved through three structural modifications: Aib substitution at position 8, lysine substitution at position 34, and attachment of a C18 fatty diacid chain at position 26 via a linker enabling albumin binding. Its clinical research portfolio spans the SUSTAIN, PIONEER, and STEP trial programs.
GLP-1 Receptor Pharmacology Research
Preclinical and clinical research has extensively characterized semaglutide's interactions with the GLP-1 receptor, a class B GPCR expressed in pancreatic beta cells, the gastrointestinal tract, the central nervous system, and the heart. Studies have examined its activation of cAMP/PKA and beta-arrestin signaling pathways.
Pancreatic Beta Cell and Incretin Research
Research has examined semaglutide's effects on glucose-stimulated insulin secretion, glucagon suppression, and gastric emptying regulation. Clinical studies in the SUSTAIN program have generated extensive data on its glucose-lowering mechanisms.
Central Nervous System and Appetite Research
A significant area of semaglutide research involves its central nervous system effects through GLP-1R expression in hypothalamic and brainstem nuclei, including its interactions with appetite-regulating NPY/AgRP and POMC/CART neuronal populations.
• Lau J et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380.
• Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.
